RNA editing derived epitopes function as cancer antigens to elicit immune responses

被引:0
作者
Minying Zhang
Jens Fritsche
Jason Roszik
Leila J. Williams
Xinxin Peng
Yulun Chiu
Chih-Chiang Tsou
Franziska Hoffgaard
Valentina Goldfinger
Oliver Schoor
Amjad Talukder
Marie A. Forget
Cara Haymaker
Chantale Bernatchez
Leng Han
Yiu-Huen Tsang
Kathleen Kong
Xiaoyan Xu
Kenneth L. Scott
Harpreet Singh-Jasuja
Greg Lizee
Han Liang
Toni Weinschenk
Gordon B. Mills
Patrick Hwu
机构
[1] The University of Texas MD Anderson Cancer Center,Department of Melanoma Medical Oncology
[2] Immatics Biotechnologies,Department of Bioinformatics and Computation Biology
[3] The University of Texas MD Anderson Cancer Center,Department of Biochemistry and Molecular Biology
[4] The University of Texas Health Science Center at Houston McGovern Medical School,Department of Molecular and Human Genetics
[5] Baylor College of Medicine,Department of Pathophysiology, College of Basic Medicine
[6] China Medical University,Department of Systems Biology
[7] Immatics US,undefined
[8] The University of Texas MD Anderson Cancer Center,undefined
来源
Nature Communications | / 9卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
In addition to genomic mutations, RNA editing is another major mechanism creating sequence variations in proteins by introducing nucleotide changes in mRNA sequences. Deregulated RNA editing contributes to different types of human diseases, including cancers. Here we report that peptides generated as a consequence of RNA editing are indeed naturally presented by human leukocyte antigen (HLA) molecules. We provide evidence that effector CD8+ T cells specific for edited peptides derived from cyclin I are present in human tumours and attack tumour cells that are presenting these epitopes. We show that subpopulations of cancer patients have increased peptide levels and that levels of edited RNA correlate with peptide copy numbers. These findings demonstrate that RNA editing extends the classes of HLA presented self-antigens and that these antigens can be recognised by the immune system.
引用
收藏
相关论文
共 181 条
[1]  
Pardoll DM(2012)Immunology beats cancer: a blueprint for successful translation Nat. Immunol. 13 1129-1132
[2]  
Tscharke DC(2015)Sizing up the key determinants of the CD8( + ) T cell response Nat. Rev. Immunol. 15 705-716
[3]  
Croft NP(2014)Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease Cancer Immunol. Immunother. 63 1341-1346
[4]  
Doherty PC(2012)Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients Clin. Cancer Res. 18 6758-6770
[5]  
La Gruta NL(2012)Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N. Engl. J. Med. 366 2443-2454
[6]  
Pedersen M(2008)Personalized vaccines: the emerging field of vaccinomics Expert. Opin. Biol. Ther. 8 1659-1667
[7]  
Radvanyi LG(2013)Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells Nat. Med. 19 747-752
[8]  
Topalian SL(2014)Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy Nat. Rev. Cancer 14 135-146
[9]  
Poland GA(2017)Personalized T cell-mediated cancer immunotherapy: progress and challenges Curr. Opin. Biotechnol. 48 142-152
[10]  
Ovsyannikova IG(2015)Neoantigens in cancer immunotherapy Science 348 69-74